Researchers developed MassiveFold, an enhanced AlphaFold version optimized for parallel processing, which accelerates protein ...

Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated cell therapies for the treatment of cancer and autoimmune diseases, today ...

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

NextCure (NXTC) reported pre-clinical data from LNCB74, a B7-H4-targeting antibody-drug conjugate, or ADC, being developed in partnership with ...

At CPHI Milan 2024, Abzena showcased its latest innovations in cell line development and ADC manufacturing, featuring the ...

Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and ...

Planegg/Martinsried, November 11, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (TCR ...

Scarring of heart tissue can be slowed but not stopped, and can lead to heart failure. But a new study has shown that an ...

Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by ...

Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC <a target=_blank href=http ...